Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Cancer; gastrointestinal; inflammation

January 3, 2019 1:47 PM UTC

Mouse studies suggest inhibiting SPR could help treat colitis and asthma, and its biosynthetic product THB could help treat breast cancer. In a xenograft mouse model of breast cancer, THB decreased tumor growth and increased T cell numbers in tumors compared with vehicle. In a mouse model of colitis, a tool compound SPR inhibitor decreased T cell infiltration in the intestine and scores of colitis severity. In a mouse model of ovalbumin-induced asthma, the SPR inhibitor decreased numbers of immune cells in bronchoalveolar lavage. Next steps could include testing THB in additional models of breast cancer and SPR inhibitors in additional models of colitis and asthma...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article